Rizvi et al. 2015 first demonstrated tumor regression of non-small cell lung cancer (NSCLC) following pembrolizumab (a PD-1 inhibitor) treatment, particularly in tumor with high TMB expression, which led to an upregulation of neoantigen-specific CD8+ T cell responses [15]. This evidence concerns the gene CD8A and neoplasm.